Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. The company is developing L-DOS47 for the treatment of non-squamous small cell lung cancer, as well as for colon, pancreas, and breast cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. The company has collaboration agreement with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. Helix BioPharma Corp. is headquartered in Richmond Hill, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone905-841-2300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
Next Earnings Date10/25/2019 (Estimated)
OptionableNot Optionable
Helix Biopharma (OTCMKTS:HBPCF) Frequently Asked Questions
What is Helix Biopharma's stock symbol?
Helix Biopharma trades on the OTCMKTS under the ticker symbol "HBPCF."
When is Helix Biopharma's next earnings date?
Has Helix Biopharma been receiving favorable news coverage?
Press coverage about HBPCF stock has trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Helix Biopharma earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Helix Biopharma.
Who are some of Helix Biopharma's key competitors?
Some companies that are related to Helix Biopharma include Progenics Pharmaceuticals (PGNX), Evolus (EOLS), Avedro (AVDR), Crinetics Pharmaceuticals (CRNX), Synthorx (THOR), Stemline Therapeutics (STML), Beyondspring (BYSI), AMAG Pharmaceuticals (AMAG), Assembly Biosciences (ASMB), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Verrica Pharmaceuticals (VRCA), Magenta Therapeutics (MGTA), Kadmon (KDMN) and DURECT (DRRX).
Who are Helix Biopharma's key executives?
Helix Biopharma's management team includes the folowing people:
- Dr. Heman Chao, CEO, Chief Scientific Officer, Member of Scientific & Strategic Advisory Board and Director (Age 56)
- Mr. Photios Michalargias, CFO & Corp. Sec. (Age 56)
- Mr. Pawel Wisniewski, Chief Exec. Officer of Poland
- Dr. Trevor Seaton M.D., FRCP(C), Vice Chairman of Medical Advisory Board
How do I buy shares of Helix Biopharma?
Shares of HBPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Helix Biopharma's stock price today?
One share of HBPCF stock can currently be purchased for approximately $0.87.
How big of a company is Helix Biopharma?
What is Helix Biopharma's official website?
How can I contact Helix Biopharma?
Helix Biopharma's mailing address is 9120 Leslie Street Suite 205, Richmond Hill A6, L4B3J9. The company can be reached via phone at 905-841-2300 or via email at [email protected]
MarketBeat Community Rating for Helix Biopharma (OTCMKTS HBPCF)
MarketBeat's community ratings are surveys of what our community members think about Helix Biopharma and other stocks. Vote "Outperform" if you believe HBPCF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBPCF will underperform the S&P 500 over the long term. You may vote once every thirty days.
